[Tolerance of the polyvalent adsorbed influenza vaccine Alorbat].
A good local and systemic tolerance of the influenza virus vaccine Alorbat was observed after a single administration in 469 patients or after a second administration within 4--6 weeks in 132 patients. An improved manufacturing process led to a higher purity of the vaccine (less protein) and therefore to a diminuation of systemic reactions. In most cases, the local reactions observed cannot be attributed to a local irritation by the vaccine but rather to mechanical damage to the skin and subcutaneous tissue after injection with a jet injector. None of the side-effects necessitated medical treatment as the systemic reactions regressed within a few hours and the local reactions disappeared spontaneously within a few days.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects*; D007251:Influenza, Human / Q000517:prevention & control; D008297:Male; D008875:Middle Aged
D007252:Influenza Vaccines
Zur Verträglichkeit des polyvalenten Grippe-Adsorbat-Impfstoffes Alorbat.